
GUIDANCE ON INITIAL ANTIBIOTIC MANAGEMENT OF NEUTROPENIC SEPSIS/FEBRILE NEUTROPENIA IN ADULT CANCER PATIENTS (including HAEMATO-ONCOLOGY)

This guidance has been developed for local adaptation to reflect local resistance rates. In addition previous microbiology results should be reviewed for resistance on an individual patient basis.



*Antimicrobial cover for specific additional infection risks:

- IV vancomycin or teicoplanin (following local guidelines) if recent infection with MRSA, MRSA colonised (current or previous), suspected central line infection or signs of skin/soft tissue infection.
- 2. IV clarithromycin 500mg 12 hourly if Community Acquired Pneumonia suspected and atypical cover required (check drug interactions)

Review date: July 2022

Cautions

- 1. Suggested antibiotic dosage is based on normal renal function
- 2. If using gentamicin / vancomycin combination potential for additive adverse renal effects. Consider teicoplanin in place of vancomycin. Monitor renal function closely
- 3. Seek early appropriate senior specialist advice and refer patient to specialist haemato-oncology/ transplant unit
- Seek senior specialist advice before using gentamicin in myeloma patients due to the risk of renal toxicity Δ

Initial version of guidance developed by the Scottish Antimicrobial Prescribing Group in collaboration with the regional cancer networks and the Scottish Microbiology and Virology Network.

YES

Start IV vancomycin or teicoplanin Plus IV gentamicin or amikacin (local epidemiology dictates choice - follow local guidelines) Plus either IV ciprofloxacin 400mg every 8 hours or IV aztreonam 2g

• Note quinolone not recommended if used as prophylaxis - use

Alternative regime if non-severe penicillin allergy: IV ceftazidime

Consider meropenem if previous or suspected ESBL

